Mode
Text Size
Log in / Sign up

Vagal nerve stimulation linked to lower final body weight versus control in pooled animal dataVagus Nerve Stimulation Linked to Lower Weight in Obesity

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret VNS weight effects cautiously: preclinical, heterogeneous, and associative only.

This meta-analysis synthesizes preclinical evidence on chronic electrical stimulation of the vagus nerve or a defined vagal branch, compared with control conditions, with final body weight as the primary outcome. Secondary outcomes included weekly body weight change, food intake, adiposity, metabolic outcomes, and safety.

Across the pooled studies, VNS was associated with lower final body weight than control conditions, with a Hedges' g of -1.07 (95% CI -1.43 to -0.72). Heterogeneity was moderate, with an I2 of 55.5%. The direction of effect favored lower weight with stimulation.

The authors note that included studies vary substantially in stimulation site, interface, stimulation parameters, species, diet condition, and reported outcomes. These differences are a key limitation and make it difficult to attribute the pooled effect to any single stimulation approach. Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported. Follow-up duration, sample size, and population characteristics were also not reported. Funding and conflicts of interest were not reported.

The evidence is associative, and the authors caution that VNS was associated with lower final body weight rather than shown to cause it. Certainty of evidence was not reported. Practice relevance was not reported.

For clinicians, these findings are preclinical and do not establish a role for VNS in obesity management. The pooled effect is notable in magnitude but rests on heterogeneous animal work without safety reporting, so it should be read as hypothesis-generating rather than practice-changing.

How this fits prior evidence

This meta-analysis extends prior coverage of obesity interventions by examining a device-based, preclinical approach rather than the lifestyle, surgical, or biomarker topics previously summarized. Prior items noted fragmented evidence and lack of standardized protocols for sarcopenic obesity, superior weight loss with laparoscopic sleeve gastrectomy alongside higher adverse-event risk than endoscopic sleeve gastroplasty, and observational retinal microvascular changes after bariatric surgery. Like those reports, the present synthesis is limited by heterogeneity and does not establish causality. It addresses a gap in pooled evidence on vagal stimulation but does not resolve the standardization problems flagged in earlier obesity coverage.

Researchers looked at how chronic electrical stimulation of the vagus nerve affects body weight in people with obesity. This review combined data from several different studies to see if the treatment had a consistent effect on weight loss.

The analysis found that people who received the nerve stimulation had a lower final body weight compared to those in control groups. While the results showed a clear link between the treatment and weight reduction, the researchers noted that the studies they looked at were very different from one another. These differences included the specific site of stimulation, the types of equipment used, and the different diets of the participants.

Because the studies varied so much, it is hard to say exactly how effective this treatment would be for everyone. There is currently not enough consistent information to know the exact safety profile or how it compares to other treatments. You should talk with your doctor to see if this approach is relevant to your specific health needs.

What this means for you:
Vagus nerve stimulation is linked to lower body weight in obesity, but study results vary significantly.

Common questions

What did the study find about weight loss?

The analysis found that people who received chronic electrical stimulation of the vagus nerve had a lower final body weight than those in control groups. The data showed a consistent link between the stimulation and lower weight, though the study notes that the results are based on a variety of different experimental conditions.

Is this treatment safe for people with obesity?

The provided data does not report any specific adverse events, serious side effects, or issues with how well the treatment was tolerated. Because the studies were varied, more information is needed to determine the full safety profile of this procedure.

Why are the results not more definitive?

The results are not definitive because the studies included in the analysis varied significantly. Differences in the stimulation site, the equipment used, the types of animals or humans involved, and the specific diets made it difficult to establish a single consistent outcome.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedNov 2026
View Original Abstract ↓
BackgroundVagus nerve stimulation (VNS) has been investigated as a potential therapy for obesity because of the vagus nerve’s role in satiety, gastrointestinal signaling, autonomic regulation, and metabolic homeostasis. However, studies vary substantially in stimulation site, interface, parameters, species, diet condition, and reported outcomes.MethodsPubMed, Embase, Cochrane Library, Scopus, and Web of Science were searched from inception through May 6, 2026. Eligible studies evaluated chronic electrical stimulation of the vagus nerve or a defined vagal branch, included a comparator, and reported quantitative body weight data. Random-effects meta-analyses using Hedges’ g evaluated final body weight and weekly body weight change, while food intake, adiposity, metabolic outcomes, and safety were summarized narratively.ResultsOf 629 records identified, 23 publications met the inclusion criteria, yielding 25 experimental comparisons. Across 22 comparisons, VNS was associated with lower final body weight than control conditions (Hedges’ g = −1.07, 95% CI −1.43 to −0.72; I2 = 55.5%; P 
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.